X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SANOFI INDIA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SANOFI INDIA GSK PHARMA/
SANOFI INDIA
 
P/E (TTM) x 62.7 33.7 185.9% View Chart
P/BV x 10.1 6.4 156.8% View Chart
Dividend Yield % 1.3 1.4 89.5%  

Financials

 GSK PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
SANOFI INDIA
Dec-16
GSK PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3,8384,560 84.2%   
Low Rs2,6374,400 59.9%   
Sales per share (Unadj.) Rs354.21,028.5 34.4%  
Earnings per share (Unadj.) Rs39.8129.0 30.8%  
Cash flow per share (Unadj.) Rs42.9186.0 23.1%  
Dividends per share (Unadj.) Rs30.0068.00 44.1%  
Dividend yield (eoy) %0.91.5 61.0%  
Book value per share (Unadj.) Rs236.9753.6 31.4%  
Shares outstanding (eoy) m84.7023.03 367.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.14.4 209.8%   
Avg P/E ratio x81.434.7 234.4%  
P/CF ratio (eoy) x75.524.1 313.5%  
Price / Book Value ratio x13.75.9 229.9%  
Dividend payout %75.452.7 143.1%   
Avg Mkt Cap Rs m274,216103,174 265.8%   
No. of employees `0004.73.6 129.6%   
Total wages/salary Rs m4,8303,592 134.5%   
Avg. sales/employee Rs Th6,387.06,537.7 97.7%   
Avg. wages/employee Rs Th1,028.3991.4 103.7%   
Avg. net profit/employee Rs Th717.1819.8 87.5%   
INCOME DATA
Net Sales Rs m30,00023,686 126.7%  
Other income Rs m728708 102.9%   
Total revenues Rs m30,72824,394 126.0%   
Gross profit Rs m4,1905,281 79.3%  
Depreciation Rs m2631,313 20.0%   
Interest Rs m015 0.0%   
Profit before tax Rs m4,6554,661 99.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7441,691 103.1%   
Profit after tax Rs m3,3682,970 113.4%  
Gross profit margin %14.022.3 62.6%  
Effective tax rate %37.536.3 103.3%   
Net profit margin %11.212.5 89.5%  
BALANCE SHEET DATA
Current assets Rs m16,74215,673 106.8%   
Current liabilities Rs m7,2026,678 107.9%   
Net working cap to sales %31.838.0 83.7%  
Current ratio x2.32.3 99.0%  
Inventory Days Days5276 68.2%  
Debtors Days Days2122 93.1%  
Net fixed assets Rs m8,6358,098 106.6%   
Share capital Rs m847230 367.8%   
"Free" reserves Rs m19,22217,088 112.5%   
Net worth Rs m20,06917,356 115.6%   
Long term debt Rs m100-   
Total assets Rs m30,03825,400 118.3%  
Interest coverage xNM311.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.00.9 107.1%   
Return on assets %11.211.8 95.4%  
Return on equity %16.817.1 98.1%  
Return on capital %25.526.9 94.5%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m5287,145 7.4%   
Fx outflow Rs m7,1936,846 105.1%   
Net fx Rs m-6,665299 -2,229.1%   
CASH FLOW
From Operations Rs m2,3603,226 73.2%  
From Investments Rs m3,008-1,555 -193.4%  
From Financial Activity Rs m-5,108-1,818 280.9%  
Net Cashflow Rs m260-147 -177.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 60.4 83.9%  
Indian inst/Mut Fund % 10.2 14.4 70.8%  
FIIs % 23.8 14.6 163.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   102,036 15,184 672.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  DISHMAN PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS